BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Focal Segmental Glomerulosclerosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Focal Segmental Glome
 rulosclerosis\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05003986-10808@assetmemo.bio
DTSTAMP:20261121T005336Z
DTSTART;VALUE=DATE:20270312
DTEND;VALUE=DATE:20270313
SUMMARY:Filspari (sparsentan): Phase 2 readout est. (NCT05003986)
DESCRIPTION:Filspari (sparsentan)\, phase 2\, Focal Segmental Glomeruloscle
 rosis.\nStudy: Study of Sparsentan Treatment in Pediatrics With Proteinuri
 c Glomerular Diseases\nEstimated primary completion: 12 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sparsentan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05003986
URL:https://assetmemo.bio/drug/sparsentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268638-940@assetmemo.bio
DTSTAMP:20261121T005336Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Praliciguat: Phase 2 readout est. (NCT07268638)
DESCRIPTION:Praliciguat\, phase 2\, Chronic Kidney Disease.\nStudy: A Study
  of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (F
 SGS)\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/praliciguat#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07268638
URL:https://assetmemo.bio/drug/praliciguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220083-902@assetmemo.bio
DTSTAMP:20261121T005336Z
DTSTART;VALUE=DATE:20281227
DTEND;VALUE=DATE:20281228
SUMMARY:Apecotrep: Phase 3 readout est. (NCT07220083)
DESCRIPTION:Apecotrep\, phase 3\, Chronic Kidney Disease.\nStudy: A Study t
 o Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Conditi
 on Called Focal Segmental Glomerulosclerosis (FSGS)\nEstimated primary com
 pletion: 27 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/apecotrep#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07220083
URL:https://assetmemo.bio/drug/apecotrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
